SEC Tracker
Get the app

Sionna Therapeutics SION

Sionna Therapeutics reports Q3 2026 results

Sionna Therapeutics (SION) filed an 8-K with the SEC on Nov 10, 2026, 7:06 am ET. Source: the filing on SEC EDGAR.

Item 2.02 Reports results

Form
8-K
Filed
Importance
Major
  1. Net loss of $32.4 million for Q3 2026
  2. Cash position of $249.8 million as of Sept 30, 2026
  3. Plans to initiate AscenSION CF Phase 2 trial in Q1 2027
  4. Workforce reduced by 46% in Sept 2026

Written from the 8-K on EDGAR. AI can make mistakes. Check the filing.

Get the appView on EDGAR

Get an email when Sionna Therapeutics files

Only major filings: results, leadership changes, listing notices and other major events, each with the plain-English summary when we have one or the key facts and the EDGAR link. Routine insider filings never email. Confirm once; unsubscribe in one click.

Data on this page was fetched . The filing on SEC.gov is the record.